Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22229
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Loh, Zoe | - |
dc.contributor.author | Mitchell, Paul L R | - |
dc.contributor.author | John, Thomas | - |
dc.contributor.author | Arulananda, Surein | - |
dc.date.accessioned | 2019-12-12T23:08:22Z | - |
dc.date.available | 2019-12-12T23:08:22Z | - |
dc.date.issued | 2019-12 | - |
dc.identifier.citation | Internal Medicine Journal 2019; 49(12): 1541-1545 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/22229 | - |
dc.description.abstract | First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine. | - |
dc.language.iso | eng | - |
dc.subject | RET rearrangement | - |
dc.subject | genomic profiling | - |
dc.subject | non-small-cell lung cancer | - |
dc.subject | tyrosine kinase inhibitor | - |
dc.subject | vandetanib | - |
dc.title | RET-rearranged non-small-cell lung cancer and therapeutic implications. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Internal Medicine Journal | - |
dc.identifier.affiliation | Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia | en |
dc.identifier.doi | 10.1111/imj.14654 | - |
dc.identifier.orcid | 0000-0002-9215-1441 | - |
dc.identifier.orcid | 0000-0002-5636-6381 | - |
dc.identifier.pubmedid | 31808254 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | John, Thomas | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.